These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 3190793)
21. In vitro and in vivo augmentation by muroctasin of the production of the third component of complement by murine macrophages. Endo N Arzneimittelforschung; 1988 Jul; 38(7A):993-6. PubMed ID: 3190805 [TBL] [Abstract][Full Text] [Related]
22. Restorative activity of muroctasin on leukopenia associated with anticancer treatment. Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800 [TBL] [Abstract][Full Text] [Related]
24. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin. Yamaguchi F; Akasaki M; Tsukada W Arzneimittelforschung; 1988 Jul; 38(7A):980-3. PubMed ID: 3263869 [TBL] [Abstract][Full Text] [Related]
25. Acute toxicity of muroctasin in mice, rats and dogs. Ono Y; Iwasaki T; Furuhama K; Onodera T Arzneimittelforschung; 1988 Jul; 38(7A):1022-4. PubMed ID: 3190794 [TBL] [Abstract][Full Text] [Related]
26. [Muroctasin, a muramyl dipeptide derivative]. Sosnowska D; Dzierzbicka K; Myśliwski A; Kołodziejczyk AM Postepy Hig Med Dosw; 1992; 46(5):521-30. PubMed ID: 1298958 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin. Ogawa T; Kotani S; Shimauchi H Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542 [TBL] [Abstract][Full Text] [Related]
28. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation. Nagao S; Sato K; Osada Y Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442 [TBL] [Abstract][Full Text] [Related]
29. Elevation by muroctasin of the serum level of the complement subcomponent C1q in mice and of its biosynthesis by cultured mouse peritoneal macrophages. Endo N; Okuda T; Osada Y; Zen-yoji H Arzneimittelforschung; 1990 Jan; 40(1):58-61. PubMed ID: 2340001 [TBL] [Abstract][Full Text] [Related]
30. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin. Ogawa T; Kotani S; Shimauchi H Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372 [TBL] [Abstract][Full Text] [Related]
31. Stimulation of macrophages by muroctasin to produce colony-stimulating factors. Akahane K; Yamaguchi F; Kita Y; Une T; Osada Y Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):179-83. PubMed ID: 1692219 [TBL] [Abstract][Full Text] [Related]
32. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection. Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831 [TBL] [Abstract][Full Text] [Related]
33. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18). Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801 [No Abstract] [Full Text] [Related]
34. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18). Akasaki M; Takashi T; Kita Y; Tsukada W Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323 [TBL] [Abstract][Full Text] [Related]
35. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice. Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426 [TBL] [Abstract][Full Text] [Related]
36. Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method. Fukuoka M; Takada M; Takifuji N; Sakai N; Ryu S; Masuda N; Matsui K; Negoro S; Kusunoki Y; Tubura E Arzneimittelforschung; 1989 Jan; 39(1):90-3. PubMed ID: 2719748 [TBL] [Abstract][Full Text] [Related]
37. Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide. Shimoda K; Okamura S; Harada N; Omori F; Niho Y Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):289-96. PubMed ID: 2093210 [TBL] [Abstract][Full Text] [Related]
38. Muroctasin [MDP-Lys(18)] augments the production of granulocyte colony-stimulating factor (G-CSF) from human peripheral blood mononuclear cells in vitro. Shimoda K; Okamura S; Kawasaki C; Omori F; Matsuguchi T; Niho Y Int J Immunopharmacol; 1990; 12(7):729-36. PubMed ID: 1705535 [TBL] [Abstract][Full Text] [Related]
39. Hematological response to the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. A randomized crossover trial. Hiraoka A; Masaoka T; Satoh T; Ota K; Oyama A; Horiuchi A; Hasegawa H; Nagai K; Kosaki M; Kanemaru A Arzneimittelforschung; 1988 Oct; 38(10):1499-501. PubMed ID: 3058133 [TBL] [Abstract][Full Text] [Related]
40. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid. Sugawara T; Takada S; Miyamoto M; Nomura M; Kato M Inflammation; 1996 Feb; 20(1):43-56. PubMed ID: 8926048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]